BioSpace News Archive

Kidneys are among the most vital organs of the human body. Kidneys act as blood filters, reabsorbing the essential elements and removing the water-soluble waste products from the blood.

Rapidly growing popularity of minimally invasive surgical options such as LASIK will accelerate demand for ophthalmic surgical systems in future years.

Increasing geriatric populace is predicted to raise the demand for specialty medical chairs. It has been estimated that the number of people aged 65 years and above in the United States will surpass 98 million by 2060, according to United States Census Bureau.

RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat severe COVID-19 patients, announced that its Board of Directors approved an increase of the Company’s registered share capital from 3,246,727,248 to 3,371,727,248 shares through the issuance of 125,000,000 shares at an issue price of CHF 0.01.

Genentech, a member of the Roche Group, announced that the company is voluntarily withdrawing the U.S. indication for Tecentriq® in prior-platinum treated metastatic urothelial carcinoma.

Oncopeptides AB, a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, announced that it strengthens the leadership of the European operations by appointing Andrea Passalacqua as General Manager in Europe, and Pamela Bacon as Head of Medical Affairs Europe.

Avacta’s AffiDX SARS-CoV-2 lateral flow test detects both B117 ‘Kent’ and D614G variants of the virus

Steba Biotech, the IMmune Photo Activate Cancer Treatment specialist announces the U.S. Food and Drug Administration granted Orphan Drug Designation to Padeliporfin ImPACT for the treatment of adult patients with Upper Tract Urothelial Cancer.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation at the H.C. Wainwright Global Life Sciences Conference.

Nonacus, a provider of genetic testing products for precision medicine and liquid biopsy, announced the commercial launch of a new service for Whole Genome Sequencing of SARS-CoV-2, developed to enable the UK government’s Test-To-Release scheme.